NCT00522808View on ClinicalTrials.gov

A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

May 31, 2008

Conditions

Chronic Hepatitis C

Interventions

DRUG

A-831

Trial Locations (3)

Unknown

ACS, Auckland

B15 2TH

Birmingham WTCRF, Birmingham

DD1 9SY

DDS, Dundee

Sponsors

Lead Sponsor

Arrow Therapeutics

All Listed Sponsors

collaborator

DDS, Dundee

UNKNOWN

collaborator

David Mutimer, Birmingham

UNKNOWN

collaborator

Ed Gane, ACS New Zealand

UNKNOWN

lead

Arrow Therapeutics

INDUSTRY

NCT00522808 - A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers | Biotech Hunter | Biotech Hunter